06628.HK
Transcenta Holding Limited
HKSE · Healthcare · Biotechnology · CN
HKD 1.03
+1.49%Year over year
Reported trailing growth
- Revenue
- -34.0%
- EBITDA
- +33.4%
- EBIT
- +28.5%
- EPS
- +31.4%
- Free cash flow
- +33.9%
- Operating cash flow
- +36.6%
Forward estimates
Based on analyst estimates
- Revenue
- +2389.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -58.6%
- EBITDA
- +34.3%
- EBIT
- +30.3%
- Net income
- +31.6%
- EPS
- +33.3%
- Free cash flow
- +33.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025